TTF1 and non-small cell lung carcinoma: Furthermore, Hsu et al. demonstrated that lung cancer cell lines, showing coactivation of the TTF-1 and NKX2–8 pathways, exhibit resistance to cisplatin, which is a standard of care in the treatment of NSCLC [40].